Scientific Background and Mechanism of Action
CJC-1295 (No DAC) is a modified 29-amino acid peptide derived from GHRH (1-29) with enhanced stability and affinity for the GHRH receptor. Upon binding to its receptor on pituitary somatotrophs, it activates adenylate cyclase and cAMP signalling pathways, leading to a natural, transient release of growth hormone. Its short half-life mimics physiological GH pulses seen in circadian rhythms — a key advantage for research that seeks to preserve feedback integrity and avoid receptor down-regulation. Compared to the DAC form, which prolongs GH release through albumin binding, the No DAC variant is preferred in studies examining natural pulsatility and GH feedback loops under short-duration kinetics.
Synergy with Ipamorelin
CJC-1295 (No DAC) and Ipamorelin form a gold-standard research pair within the GH axis model. While CJC-1295 acts as a GHRH analogue stimulating the hypothalamus and pituitary, Ipamorelin functions as a ghrelin receptor agonist directly on the pituitary to release GH. This dual-pathway activation creates a synergistic and physiological GH pulse, replicating the endocrine rhythm observed in healthy biological systems. The combination has become the benchmark in controlled laboratory research examining GH secretion, IGF-1 production, metabolic homeostasis, and anabolic gene activation. When paired, CJC-1295 (No DAC) provides the rhythmic GHRH stimulation while Ipamorelin enhances amplitude and frequency of GH release without affecting cortisol or prolactin levels.
Formats Available
Format Volume Strength Purity Description 300-Click Precision Dial-Click sealed containment device 3ml 2mg >99% Pre-mixed & pre-filled precision sealed containment device. containing 300 calibrated clicks for precise and reproducible laboratory use.
What the Research Has Shown
Why It Is Commonly Researched Alongside Ipamorelin
CJC-1295 (No-DAC) is frequently discussed alongside Ipamorelin in the literature because both support pulse-like growth hormone release rather than prolonged signalling.
CJC-1295 acts via the GHRH receptor, while Ipamorelin works through the ghrelin receptor. Together, they allow researchers to study growth hormone pulses more closely aligned with natural physiological rhythms.
What the Research Has Shown
Research has shown that CJC-1295 (No-DAC) can stimulate measurable increases in growth hormone and downstream markers such as IGF-1 in experimental settings.
Because of its shorter activity window, the No-DAC variant is commonly used where transient, controlled hormone release is the primary research objective.
Analytical Reference Calculator (Research Use Only)
The Genetra Research Calculator supports laboratory teams in planning precise measurement of peptide quantities held within sealed containment devices. Select either the Vial format or the Pre-filled sealed containment device offering 300 precise clicks for endocrine research delivery and enter the relevant values to automatically determine the calculated concentration and the corresponding dispensing volume or device increments.
Created to standardise analytical preparation and maintain consistency during experimental workflows, this calculator provides a straightforward way to derive mass-to-volume relationships and approximate microgram values for research planning. All figures displayed are indicative calculations only and must not be interpreted as guidance for administration, clinical use, or therapeutic dosing.
For Vial Calculations
The calculator will display the corresponding solution concentration, equivalent microgram value, and dispensing volume required.
For Pre-filled Sealed Containment Device Calculations
(Pre-filled sealed containment device offering 300 precise clicks for endocrine research delivery)
The calculator will output the corresponding solution concentration, equivalent microgram value, dispensing volume, and approximate precision click increments for laboratory dispensing.
Important: All calculations are indicative and provided strictly for laboratory planning and analytical reference. This tool must not be used to inform clinical, human, or veterinary dosing, administration, or therapeutic decision-making.